Crizotinib has been successfully used in the clinic to treat ALK‐rearranged NSCLC, and patients always have a median progression‐free survival (PFS) time of 10.9 months after crizotinib treatment (Gadgeel, 2017). This evidence concerns the gene ALK and non-small cell lung carcinoma.